Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Oct 31;38(11):2617-2626.
doi: 10.1093/ndt/gfad110.

Associations with age and glomerular filtration rate in a referred population with chronic kidney disease: methods and baseline data from a UK multicentre cohort study (NURTuRE-CKD)

Maarten W Taal  1   2 , Bethany Lucas  1   2 , Paul Roderick  3 , Paul Cockwell  4 , David C Wheeler  5 , Moin A Saleem  6 , Simon D S Fraser  3 , Rosamonde E Banks  7 , Tim Johnson  8 , Lorna J Hale  9 , Uwe Andag  10 , Philipp Skroblin  10 , Michaela Bayerlova  10 , Robert Unwin  11 , Nicolas Vuilleumier  12 , Rodolphe Dusaulcy  12 , Fiona Robertson  1 , Elizabeth Colby  6 , David Pitcher  13 , Fiona Braddon  13 , Melissa Benavente  1 , Elaine Davies  14 , Michael Nation  14 , Philip A Kalra  15
Affiliations
Multicenter Study

Associations with age and glomerular filtration rate in a referred population with chronic kidney disease: methods and baseline data from a UK multicentre cohort study (NURTuRE-CKD)

Maarten W Taal et al. Nephrol Dial Transplant. .

Abstract

Background: Chronic kidney disease (CKD) is common but heterogenous and is associated with multiple adverse outcomes. The National Unified Renal Translational Research Enterprise (NURTuRE)-CKD cohort was established to investigate risk factors for clinically important outcomes in persons with CKD referred to secondary care.

Methods: Eligible participants with CKD stages G3-4 or stages G1-2 plus albuminuria >30 mg/mmol were enrolled from 16 nephrology centres in England, Scotland and Wales from 2017 to 2019. Baseline assessment included demographic data, routine laboratory data and research samples. Clinical outcomes are being collected over 15 years by the UK Renal Registry using established data linkage. Baseline data are presented with subgroup analysis by age, sex and estimated glomerular filtration rate (eGFR).

Results: A total of 2996 participants was enrolled. Median (interquartile range) age was 66 (54-74) years, eGFR 33.8 (24.0-46.6) mL/min/1.73 m2 and urine albumin to creatinine ratio 209 (33-926) mg/g; 58.5% were male. Of these participants, 1883 (69.1%) were in high-risk CKD categories. Primary renal diagnosis was CKD of unknown cause in 32.3%, glomerular disease in 23.4% and diabetic kidney disease in 11.5%. Older participants and those with lower eGFR had higher systolic blood pressure and were less likely to be treated with renin-angiotensin system inhibitors (RASi) but were more likely to receive a statin. Female participants were less likely to receive a RASi or statin.

Conclusions: NURTuRE-CKD is a prospective cohort of persons who are at relatively high risk of adverse outcomes. Long-term follow-up and a large biorepository create opportunities for research to improve risk prediction and to investigate underlying mechanisms to inform new treatment development.

Keywords: albuminuria; chronic kidney disease; cohort study; risk profile; sex.

PubMed Disclaimer

Conflict of interest statement

M.W.T. reports consulting fees from Boehringer Ingelheim, honoraria from Bayer and support to attend conferences from Bayer and a leadership role in the International Society of Nephrology; B.L. reports grant funding from the National Institute for Health Research; P.C. reports a leadership position in the UK Kidney Association; D.C.W. reports grant funding from Kidney Research UK, consultancy fees from Astellas, AstraZenca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Gilead, Janssen, ProKidney and Tricida, honoraria from Amgen, Mundipharma, Merck Sharp and Dohme and Zydus; support for attending meetings from Astellas and AstraZeneca; participation in the data safety monitoring board for the following studies: ProKidney; Galderma; Eledon and a leadership role in the International Society of Nephrology; M.A.S. reports consulting fees from Travere, Dimerix and Pfizer, honoraria from American Society of Nephrology and American Society of Paediatric Nephrology, patents in AAV gene therapy, participation in the data safety monitoring board for the ECUSTEC study, and stock options in Purespring Therapeutics; S.D.S.F. reports grant funding from Kidney Research UK; R.E.B. reports grant funding and a patent with Randox Laboratories; T.J. reports previous salary from UCB Biopharma, consulting fees from UCB Pharma and stock in UCB Pharma; L.J.H. reports salary from and stock in UCB Pharma; R.U. reports stock in AstraZeneca BioPharmaceuticals and a leadership position in the Faculty of Pharmaceutical Medicine, Royal College of Physicians (London); D.P. reports salary support from the UK Kidney Association and support to attend conferences from Travere Therapeutics Inc.; M.N. reports grant funding from AstraZeneca BioPharmaceuticals and Gore Medical; P.A.K. reports grant funding from Vifor and Astellas, consulting fees from Astra Zeneca, Vifor, Unicyte and UCB, honoraria from Vifor, Astra Zeneca and Pfizer, support for attending meetings from Pharmacosmos and Vifor. The other authors declare that they have no competing interests.

Figures

Graphical Abstract
Graphical Abstract
Figure 1:
Figure 1:
Number and proportion of participants in KDIGO CKD categories.
See this image and copyright information in PMC

References

    1. Hill NR, Fatoba ST, Oke JL et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS One 2016;11:e0158765. 10.1371/journal.pone.0158765 - DOI - PMC - PubMed
    1. Jager KJ, Kovesdy C, Langham R et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int 2019;96:1048–50. 10.1016/j.kint.2019.07.012 - DOI - PubMed
    1. Gansevoort RT, Matsushita K, van der Velde M et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes in both general and high-risk populations. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011;80:93–104. 10.1038/ki.2010.531 - DOI - PMC - PubMed
    1. Matsushita K, van der Velde M, Astor BC et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073–81. - PMC - PubMed
    1. Tangri N, Grams ME, Levey AS et al. Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis. JAMA 2016;315:164–74. 10.1001/jama.2015.18202 - DOI - PMC - PubMed

Publication types

Substances